Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
22/11/2019 | 22:13 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(b) (15-12b) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
19/11/2019 | 12:01 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
18/11/2019 | 12:02 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
12/11/2019 | 22:44 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
12/11/2019 | 15:44 | Edgar (US Regulatory) | Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
12/11/2019 | 15:35 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
12/11/2019 | 15:33 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
12/11/2019 | 15:30 | Edgar (US Regulatory) | Amended Statement of Ownership: Solicitation (sc 14d9/a) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
12/11/2019 | 15:26 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
12/11/2019 | 15:19 | Edgar (US Regulatory) | Amended Tender Offer Statement by Third Party (sc To-t/a) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
12/11/2019 | 12:07 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
17/10/2019 | 17:23 | PR Newswire (US) | Moore Kuehn, PLLC Encourages Milacron Holdings Corp. (MCRN), Ecology & Environmental, Inc. (EEI), Pivotal Software, Inc. (PVT... | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
11/10/2019 | 23:16 | Edgar (US Regulatory) | Statement of Ownership: Solicitation (sc 14d9) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
11/10/2019 | 23:09 | Edgar (US Regulatory) | Tender Offer Statement by Third Party (sc To-t) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
05/10/2019 | 00:12 | PR Newswire (US) | SHAREHOLDER ALERT: WeissLaw LLP Investigates Dova Pharmaceuticals, Inc. | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
03/10/2019 | 22:10 | Edgar (US Regulatory) | Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
01/10/2019 | 23:13 | Edgar (US Regulatory) | Written Communication Relating to an Issuer or Third Party (sc To-c) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
30/09/2019 | 15:57 | PR Newswire (US) | Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Dova Pharmaceuticals, Inc. has obtained a Fair Price in its sal... | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
30/09/2019 | 08:00 | GlobeNewswire Inc. | Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi) | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
25/09/2019 | 22:15 | GlobeNewswire Inc. | Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
03/09/2019 | 22:30 | GlobeNewswire Inc. | Dova Pharmaceuticals to Present at Upcoming Investor Conferences | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
06/08/2019 | 22:15 | GlobeNewswire Inc. | Dova Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
06/08/2019 | 13:00 | GlobeNewswire Inc. | Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
30/07/2019 | 22:15 | GlobeNewswire Inc. | Dova Pharmaceuticals to Announce Second Quarter 2019 Financial Results on August 6, 2019 | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
19/07/2019 | 13:30 | GlobeNewswire Inc. | Dova Pharmaceuticals Announces DOPTELET® (avatrombopag) Now Commercially Available in the United States for Treatment of Chr... | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
27/06/2019 | 14:05 | GlobeNewswire Inc. | Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment... | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
25/06/2019 | 14:00 | GlobeNewswire Inc. | Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (avatrombopag) for the Treatment of Thro... | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
24/06/2019 | 14:00 | GlobeNewswire Inc. | Dova Pharmaceuticals Announces Four Presentations on Avatrombopag in Patients with Chronic Immune Thrombocytopenia at the Int... | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
28/05/2019 | 22:30 | GlobeNewswire Inc. | Dova Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference | NASDAQ:DOVA | Dova Pharmaceuticals Inc |
23/05/2019 | 15:06 | PR Newswire (US) | Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Health... | NASDAQ:DOVA | Dova Pharmaceuticals Inc |